As shown in Table 1, the downregulation of TUSC7 correlated positively with several adverse clinical parameters, including male gender, positive CD38 status, elevated CLL‐IPI scores, the presence of B symptoms, low platelet count, low hemoglobin levels, and increased LDH activity. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.